1-7 of 7
Juthamas Sukbuntherng
Close
Sort by
Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Constantine S. Tam, MBBS, MD, Tanya Siddiqi, MD, John N. Allan, MD, Thomas J. Kipps, MD PhD, Ian W. Flinn, MD PhD, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Stephen Opat, Paul M. Barr, MD, Alessandra Tedeschi, MD, Ryan Jacobs, MD, Xavier C. Badoux, MBBS, FRACP, FRCPA, Paolo Ghia, MD PhD, Juthamas Sukbuntherng, PhD, Ahmed Hamed Salem, PhD FCP, Kristin Russell, BS, Karl Eckert, BA, Cathy Zhou, MS, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 35.
https://doi.org/10.1182/blood-2019-121424
Published: 2019
Journal Articles

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Clinical Trials & Observations
Paul M. Barr, Jennifer R. Brown, Peter Hillmen, Susan O'Brien, Jacqueline C. Barrientos, Nishitha M. Reddy, Steven Coutre, Stephen P. Mulligan, Ulrich Jaeger, Richard R. Furman, Florence Cymbalista, Marco Montillo, Claire Dearden, Tadeusz Robak, Carol Moreno, John M. Pagel, Jan A. Burger, Samuel Suzuki, Juthamas Sukbuntherng, George Cole, Danelle F. James, John C. Byrd
Journal: Blood
Blood (2017) 129 (19): 2612–2615.
https://doi.org/10.1182/blood-2016-12-737346
Published: 2017
Includes: Supplemental data
Journal Articles

An Open-Label, Sequential-Design Drug Interaction Study of the Effects of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults

Jan de Jong, PhD, Peter Hellemans, MD, James Jiao, PhD, Juthamas Sukbuntherng, PhD, Daniele Ouellet, PhD
Journal: Blood
Blood (2016) 128 (22): 1588.
https://doi.org/10.1182/blood.V128.22.1588.1588
Published: 2016
Journal Articles

A Drug-Drug Interaction Study of Ibrutinib with Moderate and Strong CYP3A Inhibitors in Patients with B-Cell Malignancy

Jan de Jong, PhD, Peter Hellemans, MD, Severijn De Wilde, Daniel Patricia, Tara Masterson, Georgii Manikhas, MD PhD, Alexander Myasnikov, MD PhD, Dzhelil Osmanov, MD, Raul Cordoba, MD PhD, Carlos Panizo, Loeckie de Zwart, PhD, Jan Snoeys, PhD, Vijay Chauhan, PhD, James Jiao, PhD, Juthamas Sukbuntherng, PhD, Daniele Ouellet, PhD
Journal: Blood
Blood (2016) 128 (22): 3964.
https://doi.org/10.1182/blood.V128.22.3964.3964
Published: 2016
Journal Articles

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

Patrick P. Ng, Daniel K. Lu, Juthamas Sukbuntherng, Jutta K. Neuenburg, Danelle F. James, Betty Y. Chang, PhD
Journal: Blood
Blood (2015) 126 (23): 3998.
https://doi.org/10.1182/blood.V126.23.3998.3998
Published: 2015
Journal Articles

A Selective Small Molecule Factor VIIa Inhibitor, CRA-027483, Suppresses Acute Inflammation in Mice.

Stacie A. Dalrymple, PhD, Florentino D. San Pablo, Juthamas Sukbuntherng, PhD, James W. Janc, PhD, Wendy B. Young, PhD, Dange Vijaykumar, PhD, Heleen Scheerens, PhD
Journal: Blood
Blood (2005) 106 (11): 3089.
https://doi.org/10.1182/blood.V106.11.3089.3089
Published: 2005
Journal Articles

Subcutaneous Dosing of CRA-027483, a Small Molecule FVIIa Inhibitor, Prevents Arterial Thrombosis in a Baboon Model.

Ulla M. Marzec, Juthamas Sukbuntherng, Ph.D, Stacie A. Dalrymple, Ph.D, Wendy B. Young, Ph.D, Dange Vijaykumar, PhD, Peter R. Young, Ph.D, Stephen R. Hanson, PhD
Journal: Blood
Blood (2005) 106 (11): 1867.
https://doi.org/10.1182/blood.V106.11.1867.1867
Published: 2005